Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Supermarkets make up for their low margins by a high volume of sales, and with sales of higher-margin items bought by the customers. Self-service with shopping carts (trolleys) or baskets reduces labor costs, and many supermarket chains are attempting further reduction by shifting to self-service check-outs.
On 7 September 2020, CSL signed agreements with the Australian government to supply the University of Queensland vaccine (V451) and to manufacture (with AstraZeneca) the Oxford University vaccine (AZD1222), which would yield nearly 85 million doses for Australians. The agreement was contingent on the future success of clinical trials of these vaccines. Most of the manufacture would occur in Melbourne, Australia. On 11 December 2020, after a high percentage of the University of Queensland vaccine trial participants returned "false positive" results for HIV, it was decided that vaccine development will not proceed to Phase 2/3 trials. On 23 March 2021, the Therapeutic Goods Administration provisionally approved the first batches, numbering 832,000 doses, of the Oxford–AstraZeneca COVID-19 vaccine manufactured by CSL in its plant in Broadmeadows, Victoria. The Australian Government has contracted CSL to produce 50 million doses of the vaccine.
Medical applications of radio frequency (RF) energy, in the form of electromagnetic waves (radio waves) or electrical currents, have existed for over 125 years, and now include diathermy, hyperthermy treatment of cancer, electrosurgery scalpels used to cut and cauterize in operations, and radiofrequency ablation. Magnetic resonance imaging (MRI) uses radio frequency fields to generate images of the human body.
Sources: en.wikipedia.org
Merle Sheffield, The Chain and Boom, Hudson River Valley, official website West Point Fortifications The Great Chain Chaining of the Hudson in 1778 Archived February 16, 2008, at the Wayback Machine The Great Chain Chaining The Hudson George Washington's letter about the strategic importance of the Hudson Contract for the forging of The Great Chain New York Times Article about The Chain February 17, 1895 Chain Salvaging Blurb "Revolutionary West Point: 'The Key to the Continent'",
Representative desserts are buñuelos, natillas, Maria Luisa cake, bocadillo made of guayaba (guava jelly), cocadas (coconut balls), casquitos de guayaba (candied guava peels), torta de natas, obleas, flan de mango, roscón, milhoja, manjar blanco, dulce de feijoa, dulce de papayuela, torta de mojicón, and esponjado de curuba. Typical sauces (salsas) are hogao (tomato and onion sauce) and Colombian-style ají. Some representative beverages are coffee (Tinto), champús, cholado, lulada, avena colombiana, sugarcane juice, aguapanela, aguardiente, hot chocolate and fresh fruit juices (often made with water or milk).
A letter from James Bowler, the Permanent Secretary to the Treasury, subsequently emerges in which he says the Conservative allegations "should not be presented as having been produced by the civil service". Faiza Shaheen is deselected as Labour candidate for Chingford and Woodford Green and subsequently resigns from the party. Two people are arrested after a milkshake is thrown at Reform UK leader Nigel Farage as he launches his campaign in Clacton. 5 June – Alba Party leader Alex Salmond confirms he will not stand in the general election, but instead plans to stand in the 2026 Scottish Parliament election in Banff and Buchan. First Minister of Wales Vaughan Gething loses a nonbinding vote of no confidence in the Senedd with members voting 29–27 in favour of a motion put forward by the Welsh Conservatives. It follows an investigation into the activities of a leading donor to his election campaign. Gething says he will not resign following the vote. Richard Holden is selected as the Conservative candidate for Basildon and Billericay. David Duguid is prevented from standing as the Conservative candidate in Aberdeenshire North and Moray East. Instead, Douglas Ross, who had previously intended to stand down at the election, announces he will contest the constituency at a press conference the next day. 6 June – The Office for Statistics Regulation criticises Sunak for his comments about Labour tax rises, saying most people would have been unaware the figures related to a four year period.
Sources: en.wikipedia.org
The reactivity of the reactor after the shutdown first decreases, then increases again, having a shape of a pit; this gave the "iodine pit" its name. The degree of poisoning, and the depth of the pit and the corresponding duration of the outage, depends on the neutron flux before the shutdown. Iodine pit behavior is not observed in reactors with neutron flux density below 5×1016 neutrons m−2s−1, as the 135Xe is primarily removed by decay instead of neutron capture. As the core reactivity reserve is usually limited to 10% of Dk/k, thermal power reactors tend to use neutron flux at most about 5×1013 neutrons m−2s−1 to avoid restart problems after shutdown. The concentration changes of 135Xe in the reactor core after its shutdown is determined by the short-term power history of the reactor (which determines the initial concentrations of 135I and 135Xe), and then by the half-life differences of the isotopes governing the rates of its production and removal; if the activity of 135I is higher than activity of 135Xe, the concentration of 135Xe will rise, and vice versa. During reactor operation at a given power level, a secular equilibrium is established within 40–50 hours, when the production rate of iodine-135, its decay to xenon-135, and its burning to xenon-136 and decay to caesium-135 are keeping the xenon-135 amount in the reactor constant at a given power level. The equilibrium concentration of 135I is proportional to the neutron flux φ. The equilibrium concentration of 135Xe, however, depends very little on neutron flux for φ > 1017 neutrons m−2s−1.
Ana María Muñoz Jauregui (born 1969, Lima) is a Peruvian pharmacist, biochemist and nutritionist. She has served as Rector and, since 2023, as the Vice Rector of research at San Ignacio de Loyola University (USIL). Muñoz has authored numerous publications and received national and international awards, such as silver, gold medals and semi-grand prize wins at the International KIWIE Award.
=== Other countries === Argentina: President Javier Milei supported the United States and condemned the Cuban government for "authoritarianism". On 6 May 2026, Milei said during a conference in Los Angeles that he wished that Cuba and Venezuela would reach the American Dream soon, calling it a "freedom model" and hoping that it will get to the rest of Latin America. Brazil: President Luiz Inácio Lula da Silva condemned the U.S. fuel blockade and called for humanitarian help for Cubans. Canada: Minister of Foreign Affairs Anita Anand announced C$8 million in funding to expand food and nutrition programs in Cuba in response to the humanitarian crisis, stating "as the people of Cuba face significant hardship, Canada stands in solidarity and is providing targeted assistance to help address urgent needs". Anand later announced an additional C$5.5 million in international assistance in response to the humanitarian crisis. Chile: Then-current president Gabriel Boric called the blockade "criminal" and "inhumane", saying that "nothing justifies the harm being done to boys, girls, and innocent citizens". Then-incoming president José Antonio Kast in turn disagreed with Boric's decision to send humanitarian aid, claiming that it ultimately benefits a "dictatorship". Colombia: Then-current left-wing President Gustavo Petro visited Havana and condemned U.S. pressure on Cuba.
== Other products produced == The main products of malolactic fermentation are lactic acid, diacetyl, acetic acid, acetoin, and various esters. The amount and exact nature of these products depends on the species/strain of LAB conducting the malolactic fermentation and the condition influencing that wine (pH, available nutrients, oxygen levels, etc.). Some strains of O. oeni can synthesize higher alcohols which can contribute to fruity notes in the aroma of the wine. Additionally, some strains of the bacterium have beta-glucosidase enzymes that can break down monoglucosides which are aroma compounds attached to a sugar molecule. When the sugar component is cleaved, the rest of the compound becomes volatilized, meaning it can potentially be detected in the aroma bouquet of the wine. In the early 21st century, some strains of O. oeni were shown to use acetaldehyde by breaking it down into ethanol or acetic acid. While this may help for wines with excessive levels of acetaldehyde, for red wines, it can also destabilize the color of the wine by interfering with acetaldehyde's reaction with anthocyanins to create polymeric pigments that help create a wine's color.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.